IL310346A - Muscarinic acetylcholine M4 receptor antagonists - Google Patents
Muscarinic acetylcholine M4 receptor antagonistsInfo
- Publication number
- IL310346A IL310346A IL310346A IL31034624A IL310346A IL 310346 A IL310346 A IL 310346A IL 310346 A IL310346 A IL 310346A IL 31034624 A IL31034624 A IL 31034624A IL 310346 A IL310346 A IL 310346A
- Authority
- IL
- Israel
- Prior art keywords
- antagonists
- acetylcholine receptor
- muscarinic acetylcholine
- muscarinic
- receptor
- Prior art date
Links
- 102000000413 Muscarinic acetylcholine receptor M4 Human genes 0.000 title 1
- 108050008897 Muscarinic acetylcholine receptor M4 Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762574912P | 2017-10-20 | 2017-10-20 | |
| PCT/US2018/056803 WO2019079783A1 (en) | 2017-10-20 | 2018-10-20 | ANTAGONISTS OF THE MUSCARINIC RECEPTOR OF ACETYLCHOLINE M4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL310346A true IL310346A (en) | 2024-03-01 |
Family
ID=66173904
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL310346A IL310346A (en) | 2017-10-20 | 2018-10-20 | Muscarinic acetylcholine M4 receptor antagonists |
| IL273924A IL273924B2 (en) | 2017-10-20 | 2018-10-20 | Antagonists of the muscarinic acetylcholine receptor m4 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL273924A IL273924B2 (en) | 2017-10-20 | 2018-10-20 | Antagonists of the muscarinic acetylcholine receptor m4 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11299481B2 (es) |
| EP (1) | EP3697759B1 (es) |
| JP (1) | JP7270989B2 (es) |
| KR (2) | KR102776114B1 (es) |
| CN (2) | CN118063442A (es) |
| AU (2) | AU2018351651B2 (es) |
| CA (1) | CA3079617A1 (es) |
| ES (1) | ES3064093T3 (es) |
| IL (2) | IL310346A (es) |
| WO (1) | WO2019079783A1 (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202092441A1 (ru) | 2016-06-07 | 2021-05-21 | Джакобио Фармасьютикалс Ко., Лтд. | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 |
| KR20240026521A (ko) | 2017-03-23 | 2024-02-28 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
| US12600726B2 (en) | 2017-07-12 | 2026-04-14 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| MX2020003242A (es) | 2017-09-22 | 2020-09-18 | Jubilant Epipad LLC | Compuestos heterociclicos como inhibidores de pad. |
| AU2018352142B2 (en) | 2017-10-18 | 2022-08-25 | Jubilant Epipad LLC | Imidazo-pyridine compounds as PAD inhibitors |
| IL310346A (en) * | 2017-10-20 | 2024-03-01 | Univ Vanderbilt | Muscarinic acetylcholine M4 receptor antagonists |
| AU2018360581A1 (en) | 2017-10-31 | 2020-06-11 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| KR20200085836A (ko) | 2017-11-06 | 2020-07-15 | 주빌런트 프로델 엘엘씨 | Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체 |
| BR112020010322A2 (pt) | 2017-11-24 | 2020-11-17 | Jubilant Episcribe Llc | composto da fórmula i; composto da fórmula ia; composto da fórmula ib; processo de preparação de compostos da fórmula i; composição farmacêutica; método para o tratamento e/ou prevenção de várias doenças; uso dos compostos; método para o tratamento de câncer; e método para o tratamento e/ou prevenção de uma afecção mediada por prmt5 ou um distúrbio proliferativo ou câncer |
| EP3728228A1 (en) | 2017-12-22 | 2020-10-28 | Ravenna Pharmaceuticals, Inc. | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| CN111788182B (zh) * | 2018-02-02 | 2023-09-26 | 范德堡大学 | 毒蕈碱性乙酰胆碱受体m4的拮抗剂 |
| SG11202008950PA (en) | 2018-03-13 | 2020-10-29 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation |
| CN112839935A (zh) | 2018-09-26 | 2021-05-25 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| AU2020358000A1 (en) * | 2019-10-04 | 2022-04-07 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| JP2023506740A (ja) * | 2019-12-10 | 2023-02-20 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| AU2020402978A1 (en) * | 2019-12-10 | 2022-06-23 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| WO2021174176A1 (en) * | 2020-02-28 | 2021-09-02 | Remix Therapeutics Inc. | Pyridazine dervatives for modulating nucleic acid splicing |
| US20230183218A1 (en) * | 2020-04-24 | 2023-06-15 | Vanderbilt University | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 |
| EP4139303A1 (en) * | 2020-04-24 | 2023-03-01 | Vanderbilt University | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 |
| WO2022036177A1 (en) * | 2020-08-13 | 2022-02-17 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| AU2021381350A1 (en) * | 2020-11-18 | 2023-06-08 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| CN116669737A (zh) * | 2020-12-22 | 2023-08-29 | 范德堡大学 | 毒蕈碱型乙酰胆碱受体m4的拮抗剂 |
| IL303774A (en) * | 2020-12-22 | 2023-08-01 | Univ Vanderbilt | M4 muscarinic acetylcholine receptor antagonists |
| EP4317153A4 (en) * | 2021-04-01 | 2024-02-21 | ONO Pharmaceutical Co., Ltd. | Abhd6 antagonist |
| US20240174655A1 (en) * | 2021-04-02 | 2024-05-30 | Vanderbilt University | Indazole derivatives as antagonists of the muscarinic acetylcholine receptor m4 |
| US20240228468A1 (en) * | 2021-04-05 | 2024-07-11 | Vanderbilt University | N-(6-((octahydrocyclopenta[c]pyrrol-5-yi)amino)pyridazin-3-yl)phenyl)carboxamide and (6- ((octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)benzamide derivatives as machr m4 antagonists for the treatment of neurodegenerative disorders |
| US20240360114A1 (en) * | 2021-08-09 | 2024-10-31 | Sironax Ltd. | Ferroptosis modulators, preparations, and uses thereof |
| WO2023141511A1 (en) * | 2022-01-19 | 2023-07-27 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
Family Cites Families (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5221675A (en) | 1989-12-15 | 1993-06-22 | Abbott Laboratories | Aza-spirocyclic compounds that enhance cholinergic neurotransmission |
| US5726172A (en) * | 1996-01-16 | 1998-03-10 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
| TR200100462T2 (tr) | 1998-08-18 | 2001-09-21 | Ucb, S.A. | Muskarinik agonistleri ve antagonistleri |
| US6809105B2 (en) | 2000-04-27 | 2004-10-26 | Abbott Laboratories | Diazabicyclic central nervous system active agents |
| US6995144B2 (en) | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
| CN1649845A (zh) | 2002-04-26 | 2005-08-03 | 先灵公司 | 蝇蕈碱拮抗剂 |
| EP2280003B1 (en) * | 2002-07-15 | 2014-04-02 | Symphony Evolution, Inc. | Process for preparing receptor-type kinase modulators |
| US20040044029A1 (en) | 2002-08-14 | 2004-03-04 | Dart Michael J. | Azabicyclic compounds are central nervous system active agents |
| EP1581522B1 (en) | 2002-12-23 | 2008-02-20 | Ranbaxy Laboratories Limited | Flavaxate derivatives as muscarinic receptor antagonists |
| WO2004089898A1 (en) | 2003-04-09 | 2004-10-21 | Ranbaxy Laboratories Limited | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
| PT2213661E (pt) * | 2003-09-26 | 2011-12-15 | Exelixis Inc | Moduladores de c-met e métodos de uso |
| WO2005103003A2 (en) | 2004-04-26 | 2005-11-03 | Pfizer Inc. | Pyrrolopyridine derivatives and their use as hiv-integrase inhibitors |
| DE102004039789A1 (de) | 2004-08-16 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| EP1796667A2 (en) | 2004-09-27 | 2007-06-20 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| WO2006035280A1 (en) | 2004-09-27 | 2006-04-06 | Ranbaxy Laboratories Limited | 3,4-dihydroisoquinoline compounds as muscrinic receptor antagonists for the treatment of respiratory, urinary and gastrointestinal diseases |
| GB0510204D0 (en) | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| EP1904495A2 (en) | 2005-07-11 | 2008-04-02 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
| US7560551B2 (en) | 2006-01-23 | 2009-07-14 | Amgen Inc. | Aurora kinase modulators and method of use |
| AU2007208351C1 (en) | 2006-01-23 | 2011-07-07 | Amgen Inc. | Aurora kinase modulators and method of use |
| NZ570497A (en) | 2006-02-22 | 2011-09-30 | Vertex Pharma | Spiro condensed 4,4'-quinilino-piperidines derivatives as modulators of muscarinic receptors |
| EP2038289A2 (en) | 2006-04-21 | 2009-03-25 | Amgen Inc. | Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use |
| WO2007138431A2 (en) * | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
| WO2008065500A2 (en) | 2006-11-30 | 2008-06-05 | Pfizer Products Inc. | Heteroaryl amides as type i glycine transport inhibitors |
| EP2129660A2 (en) | 2006-12-19 | 2009-12-09 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| CN101230058A (zh) | 2007-01-23 | 2008-07-30 | 上海恒瑞医药有限公司 | 双环氮杂烷类衍生物、其制备方法及其在医药上的用途 |
| EP2231672B1 (en) | 2007-11-21 | 2014-12-17 | AbbVie Inc. | BIARYL SUBSTITUTED DIAZABICYCLOHEPTANE DERIVATIVES AS nAChR MODULATORS |
| US8148408B2 (en) | 2008-05-09 | 2012-04-03 | Abbott Laboratories | Selective substituted pyridine ligands for neuronal nicotinic receptors |
| US8691865B2 (en) | 2008-11-26 | 2014-04-08 | Abbvie Inc. | Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers |
| WO2010067102A1 (en) | 2008-12-09 | 2010-06-17 | Astrazeneca Ab | Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders |
| US9034891B2 (en) | 2009-01-26 | 2015-05-19 | Israel Institute For Biological Research | Bicyclic heterocyclic spiro compounds |
| FR2945531A1 (fr) | 2009-05-12 | 2010-11-19 | Sanofi Aventis | Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique |
| WO2011084796A2 (en) * | 2009-12-21 | 2011-07-14 | Qiang Zhang | Novel quinazoline derivatives |
| WO2012047703A2 (en) | 2010-10-04 | 2012-04-12 | Schering Corporation | Cyclopropyl-spiro-piperidines useful as sodium channel blockers |
| JP2012107001A (ja) * | 2010-10-22 | 2012-06-07 | Shionogi & Co Ltd | インドールアミド化合物を含有する医薬 |
| WO2012154731A1 (en) | 2011-05-08 | 2012-11-15 | Vanderbilt University | Substituted 1h-pyrrolo[3,2-c]quinolin-4(5h)-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| KR20180084153A (ko) | 2011-06-10 | 2018-07-24 | 메르크 파텐트 게엠베하 | Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법 |
| EP3153167B1 (en) | 2011-10-28 | 2019-10-02 | Vanderbilt University | Substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
| CN103102352B (zh) * | 2011-11-15 | 2015-08-12 | 山东亨利医药科技有限责任公司 | 酪氨酸激酶抑制剂吲哚满酮衍生物 |
| KR102032934B1 (ko) | 2011-12-21 | 2019-10-16 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 피롤 6원 헤테로아릴 고리 유도체, 그의 제조 방법, 및 그의 의약 용도 |
| US8697888B2 (en) | 2012-01-06 | 2014-04-15 | Vanderbilt University | Substituted (1-(methylsulfonyl)azetidin-3-yl)(heterocycloalkyl)methanone analogs as antagonists of muscarinic acetylcholine M1 receptors |
| JP6404717B2 (ja) | 2012-03-02 | 2018-10-17 | ジェネンテック， インコーポレイテッド | アミドスピロ環状アミド及びスルホンアミド誘導体 |
| WO2014035829A1 (en) | 2012-08-31 | 2014-03-06 | Vanderbilt University | Substituted 3-aminothieno[2,3-c]pyridine-2-carboxamide analogs as positive allosteric modulators |
| US9056875B2 (en) | 2012-08-31 | 2015-06-16 | Vanderbilt University | Substituted pyrazolo[3′,4′:4,5]thieno[2,3-C]pyridazin-3-amine analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4 |
| BR112015006029B1 (pt) | 2012-09-18 | 2022-01-25 | Heptares Therapeutics Limited | Compostos aza bicíclicos como agonistas de receptor m1 muscarínicos, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para tratar um distúrbio cognitivo ou distúrbio psicótico ou para tratar ou reduzir a gravidade de dores agudas, crônicas, neuropáticas ou inflamatórias |
| KR20150072412A (ko) | 2012-10-05 | 2015-06-29 | 리겔 파마슈티칼스, 인크. | Gdf-8 억제제 |
| MX2015005375A (es) | 2012-11-07 | 2015-07-21 | Hoffmann La Roche | Compuestos de triazolo. |
| WO2014093230A2 (en) | 2012-12-10 | 2014-06-19 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity |
| TW201444820A (zh) | 2013-03-13 | 2014-12-01 | Abbvie Inc | 吡啶ｃｄｋ９激酶抑制劑 |
| SI3004076T1 (sl) | 2013-05-27 | 2020-02-28 | F. Hoffmann-La Roche Ag | Novi spojini 3,4-dihidro-2H-izokinolin-1-on in 2,3-dihidro-izoindol-1-on |
| WO2014191338A1 (en) | 2013-05-27 | 2014-12-04 | F. Hoffmann-La Roche Ag | New 3,4-dihydro-2h-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds |
| US9637498B2 (en) | 2013-08-23 | 2017-05-02 | Vanderbilt University | Substituted thieno[2,3-C]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4 |
| WO2015027204A1 (en) | 2013-08-23 | 2015-02-26 | Vanderbilt University | Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| AU2014337067B2 (en) | 2013-10-18 | 2019-01-24 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of proliferative diseases |
| BR112016008632A8 (pt) | 2013-10-21 | 2020-03-17 | Merck Patent Gmbh | compostos de heteroarila como inibidores de btk, seus usos, e composição farmacêutica |
| WO2015078374A1 (en) | 2013-11-27 | 2015-06-04 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| WO2015094803A1 (en) | 2013-12-16 | 2015-06-25 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| EP3102198B1 (en) * | 2014-02-06 | 2020-08-26 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
| KR102352388B1 (ko) | 2014-02-06 | 2022-01-17 | 헵테얼즈 테라퓨틱스 리미티드 | 무스카린성 m1 수용체 및/또는 m4 수용체 작용제로서 바이사이클릭 아자 화합물 |
| HUE038764T2 (hu) | 2014-03-17 | 2018-11-28 | Remynd Nv | 2,7-Diazaspiro[3.5]nonán vegyületek |
| MA39838B1 (fr) | 2014-04-04 | 2019-05-31 | Pfizer | Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4 |
| PE20211782A1 (es) | 2014-05-23 | 2021-09-08 | Hoffmann La Roche | Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos |
| JO3579B1 (ar) | 2014-09-26 | 2020-07-05 | Luc Therapeutics Inc | مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول |
| GB201504675D0 (en) | 2015-03-19 | 2015-05-06 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| DK3305785T3 (da) | 2015-05-29 | 2021-10-11 | Teijin Pharma Ltd | Pyrido[3,4-d]pyrimidinderivat og farmaceutisk acceptabelt salt deraf |
| UA125171C2 (uk) | 2015-07-02 | 2022-01-26 | Янссен Саєнсиз Айрленд Юсі | Антибактеріальні сполуки |
| WO2017012489A1 (zh) | 2015-07-21 | 2017-01-26 | 四川海思科制药有限公司 | 具有β2受体激动及M3受体拮抗活性的苯并环衍生物及其在医药上的用途 |
| GB201513742D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201513740D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonist |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| EP3371164B1 (en) | 2015-11-06 | 2022-03-16 | Neurocrine Biosciences, Inc. | N-[2-(1-benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases |
| WO2017083867A1 (en) | 2015-11-12 | 2017-05-18 | Afasci, Inc. | Ion channel inhibitory compounds, pharmaceutical formulations and uses |
| KR20180110132A (ko) | 2016-02-16 | 2018-10-08 | 반더빌트유니버시티 | 무스카린성 아세틸콜린 수용체 m1의 양성 알로스테릭 조절제 |
| AR108326A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
| US20170355708A1 (en) | 2016-06-09 | 2017-12-14 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| MX385384B (es) | 2016-06-22 | 2025-03-18 | Univ Vanderbilt | Moduladores alostericos positivos del receptor muscarinico de acetilcolina m4 |
| MX389592B (es) | 2016-09-02 | 2025-03-20 | Suven Life Sciences Ltd | Moduladores alostericos positivos del receptor m1 muscarinico |
| WO2018093694A1 (en) * | 2016-11-17 | 2018-05-24 | Merck Sharp & Dohme Corp. | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| WO2018226150A1 (en) | 2017-06-05 | 2018-12-13 | Medivir Aktiebolag | Pyrazolopyrimidine as malt-1 inhibitors |
| US12600726B2 (en) | 2017-07-12 | 2026-04-14 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| AU2018313802A1 (en) | 2017-08-08 | 2020-02-20 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| WO2019079410A1 (en) | 2017-10-17 | 2019-04-25 | Vanderbilt University | ANTAGONISTS OF THE MUSCARINIC RECEPTOR OF ACETYLCHOLINE M4 |
| IL310346A (en) * | 2017-10-20 | 2024-03-01 | Univ Vanderbilt | Muscarinic acetylcholine M4 receptor antagonists |
| AU2018360581A1 (en) | 2017-10-31 | 2020-06-11 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| EP3732163A4 (en) | 2017-12-20 | 2021-07-14 | Vanderbilt University | MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS |
| CN111788182B (zh) | 2018-02-02 | 2023-09-26 | 范德堡大学 | 毒蕈碱性乙酰胆碱受体m4的拮抗剂 |
| EP3810615B1 (en) | 2018-06-20 | 2026-01-28 | Merck Sharp & Dohme LLC | Arginase inhibitors and methods of use |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| AU2020358000A1 (en) | 2019-10-04 | 2022-04-07 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| AU2020402978A1 (en) * | 2019-12-10 | 2022-06-23 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| JP2023506740A (ja) * | 2019-12-10 | 2023-02-20 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| EP4139303A1 (en) * | 2020-04-24 | 2023-03-01 | Vanderbilt University | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 |
| US20230183218A1 (en) * | 2020-04-24 | 2023-06-15 | Vanderbilt University | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 |
| WO2022036177A1 (en) | 2020-08-13 | 2022-02-17 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| AU2021381350A1 (en) | 2020-11-18 | 2023-06-08 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| CN116669737A (zh) | 2020-12-22 | 2023-08-29 | 范德堡大学 | 毒蕈碱型乙酰胆碱受体m4的拮抗剂 |
| IL303774A (en) | 2020-12-22 | 2023-08-01 | Univ Vanderbilt | M4 muscarinic acetylcholine receptor antagonists |
| US20240174655A1 (en) * | 2021-04-02 | 2024-05-30 | Vanderbilt University | Indazole derivatives as antagonists of the muscarinic acetylcholine receptor m4 |
| US20240228468A1 (en) * | 2021-04-05 | 2024-07-11 | Vanderbilt University | N-(6-((octahydrocyclopenta[c]pyrrol-5-yi)amino)pyridazin-3-yl)phenyl)carboxamide and (6- ((octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)benzamide derivatives as machr m4 antagonists for the treatment of neurodegenerative disorders |
| US20240287050A1 (en) * | 2021-06-11 | 2024-08-29 | Vanderbilt University | (4-(6-((2-octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-lambda6- sulfanone derivatives and similar compounds as muscarinic acetylcholine receptor m4 antagonists for the treatment of neurodegenerative disorders |
-
2018
- 2018-10-20 IL IL310346A patent/IL310346A/en unknown
- 2018-10-20 KR KR1020207013966A patent/KR102776114B1/ko active Active
- 2018-10-20 IL IL273924A patent/IL273924B2/en unknown
- 2018-10-20 US US16/757,245 patent/US11299481B2/en active Active
- 2018-10-20 AU AU2018351651A patent/AU2018351651B2/en active Active
- 2018-10-20 EP EP18869444.2A patent/EP3697759B1/en active Active
- 2018-10-20 CN CN202410064006.9A patent/CN118063442A/zh active Pending
- 2018-10-20 ES ES18869444T patent/ES3064093T3/es active Active
- 2018-10-20 CA CA3079617A patent/CA3079617A1/en active Pending
- 2018-10-20 JP JP2020521971A patent/JP7270989B2/ja active Active
- 2018-10-20 CN CN201880081828.0A patent/CN111491920B/zh active Active
- 2018-10-20 KR KR1020257006587A patent/KR20250037575A/ko active Pending
- 2018-10-20 WO PCT/US2018/056803 patent/WO2019079783A1/en not_active Ceased
-
2022
- 2022-03-07 US US17/688,709 patent/US11820757B2/en active Active
-
2023
- 2023-04-04 AU AU2023202086A patent/AU2023202086B2/en active Active
- 2023-10-13 US US18/486,712 patent/US12577234B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL273924B1 (en) | 2024-03-01 |
| JP2021500345A (ja) | 2021-01-07 |
| KR20200074164A (ko) | 2020-06-24 |
| IL273924A (en) | 2020-05-31 |
| EP3697759B1 (en) | 2025-12-31 |
| US20220213069A1 (en) | 2022-07-07 |
| CA3079617A1 (en) | 2019-04-25 |
| KR20250037575A (ko) | 2025-03-17 |
| CN118063442A (zh) | 2024-05-24 |
| US11820757B2 (en) | 2023-11-21 |
| IL273924B2 (en) | 2024-07-01 |
| AU2023202086A1 (en) | 2023-05-04 |
| EP3697759A4 (en) | 2021-05-12 |
| JP7270989B2 (ja) | 2023-05-11 |
| US20210188820A1 (en) | 2021-06-24 |
| ES3064093T3 (en) | 2026-04-22 |
| US11299481B2 (en) | 2022-04-12 |
| AU2018351651A1 (en) | 2020-06-04 |
| AU2023202086B2 (en) | 2025-04-03 |
| CN111491920B (zh) | 2024-01-30 |
| KR102776114B1 (ko) | 2025-03-07 |
| EP3697759A1 (en) | 2020-08-26 |
| WO2019079783A1 (en) | 2019-04-25 |
| US12577234B2 (en) | 2026-03-17 |
| US20240116902A1 (en) | 2024-04-11 |
| AU2018351651B2 (en) | 2023-01-05 |
| CN111491920A (zh) | 2020-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273924A (en) | Muscarinic acetylcholine M4 receptor antagonists | |
| IL271805A (en) | M4 muscarinic acetylcholine receptor antagonists | |
| IL274062A (en) | Muscarinic acetylcholine M4 receptor antagonists | |
| ZA201808219B (en) | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 | |
| IL276411A (en) | M4 muscarinic acetylcholine receptor antagonists | |
| IL288321A (en) | Methods for treating depression using orexin-2 receptor antagonists | |
| IL247854A0 (en) | Muscarinic receptor antagonists, preparations containing them and their uses | |
| EP3732163A4 (en) | MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS | |
| IL258892B (en) | Calcitonin gene-related peptide receptor antagonists | |
| IL274883A (en) | BRADYKININ B2 receptor antagonists | |
| IL291951B1 (en) | Muscarinic M1 acetylcholine receptor antagonists | |
| EP3697781C0 (en) | MUSCARINIC ACETYLCHOLINE M4 RECEPTOR ANTAGONISTS | |
| EP3665175A4 (en) | MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS | |
| IL258893A (en) | Cgrp receptor antagonists | |
| ZA201800452B (en) | Cgrp receptor antagonists | |
| IL258894A (en) | Cgrp receptor antagonists | |
| GB201702174D0 (en) | Orexin receptor antagonists | |
| GB201707499D0 (en) | Orexin receptor antagonists | |
| HK40052415A (en) | Muscarinic acetylcholine m1 receptor antagonists | |
| GB201707504D0 (en) | Orexin receptor antagonists |